3-((4-bromophenyl)sulfonyl)-5-chloro-[1,2,3]triazolo[1,5-a]quinazoline | 1174392-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-((4-bromophenyl)sulfonyl)-5-chloro-[1,2,3]triazolo[1,5-a]quinazoline
• CAS: 1174392-44-9
• 化学式: C₁₅H₈BrClN₄O₂S
• 分子量: 423.677
• InChiKey: YOIFUGQZCAMVAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.53
• 重原子数：
  24.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.22
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  哌啶-4-甲酰胺 、 3-((4-bromophenyl)sulfonyl)-5-chloro-[1,2,3]triazolo[1,5-a]quinazoline 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-[3-(4-Bromobenzenesulfonyl)-[1,2,3]triazolo[1,5-A]quinazolin-5-YL]piperidine-4-carboxamide
  参考文献：
  名称：

  Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus

  摘要：

  A small molecule (1835F03) that inhibits Staphylococcus aureus wall teichoic acid biosynthesis, a proposed antibiotic target, has been discovered. Rapid, parallel, solution-phase synthesis was employed to generate a focused library of analogs, providing detailed information about structure-activity relationships and leading to the identification of targocil, a potent antibiotic. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.036
• 作为产物：
  描述：

  3-[(4-bromophenyl)sulfonyl][1,2,3]triazolo[1,5-a]quinazolin-5(4H)-one 在 三乙胺 、 三氯氧磷 作用下， 生成 3-((4-bromophenyl)sulfonyl)-5-chloro-[1,2,3]triazolo[1,5-a]quinazoline
  参考文献：
  名称：

  Solution Phase Parallel Synthesis of Substituted 3-Phenylsulfonyl-[1,2,3]triazolo[1,5-a]quinazolines: Selective Serotonin 5-HT₆ Receptor Antagonists

  摘要：

  Here we present the solution phase parallel synthesis of a combinatorial library consisting of 776 new substituted 3-phenylsulfonyl-[1,2,3]triazolo[1,5-a]quinazolines and a study of the relation of their structure with a 5-HT6 receptor antagonistic activity in a functional cell (HEK 293) analysis and radioligand competitive binding. We have found highly active and selective 5-HT6R antagonists. The most active 5-HT6R antagonists have IC50 < 100 nM in a functional assay, and K-i < 10 nM in a binding assay, which is 100 times higher than the activity with respect to other serotonin receptors.

  DOI：

  10.1021/cc1000049